|
Representative compound | Class/category | Mode(s) of action | Representative references |
|
Intraperitoneal compartment: disease process and inflammation |
Pycnogenol | Diet/supplement | Nuclear factor-kappa B inhibitor | [19] |
Novel compounds | Pharmaceuticals | Angiogenesis inhibition | [20, 21] |
Resveratrol, other novel compounds | Diet/supplement or pharmaceuticals | Sirtuin 1 pathway/anti-inflammatory | [22] |
Melatonin | Supplement | Antioxidant | [23–25] |
Novel compounds, vitamin D/analogues | Pharmaceuticals or vitamin D plus progesterone | Semaphorins and plexins/cell attachment | [26–29] |
Novel biopharmaceutical compounds | siRNA | Inflammatory monocytes | [30] |
AH6809, AH23848 | Prostaglandin E2 receptor (PTGER2 or PTGER4) antagonists | Prostaglandin E2 antagonism | [31–33] |
Novel compounds | Histone deacetylase inhibitors | Epigenetic modification | [1] |
|
Intraperitoneal and systemic inflammation: interface between compartments |
Statins | Well-known pharmaceuticals | Inhibition of HMG-CoA reductase and anti-inflammatory | [20, 34] |
Metformin | Well-known pharmaceutical | Anti-inflammatory | [35] |
Omega-3-fatty acid, novel compounds | Diet/supplement or pharmaceuticals | Anti-inflammatory and inflammatory monocytes via GPR120 | [36] |
Spironolactone (recent study in CAPD) | Well-known pharmaceutical | Intraperitoneal and systemic inflammatory via aldosterone receptor antagonism | [37] |
Colchicine | Well-known pharmaceutical | Intraperitoneal and systemic inflammatory via multiple modes of action | [38, 39] |
|